Disease relevance of S100A7A

• S100A15 (koebernisin)   is proinflammatory through a yet to identified Gi protein-coupled receptor. The enhanced expression of the 11.2 kDa S100A15 (koebnerisin) in psoriasis and epithelial cancers suggests that it contributes to the disease pathogenesis and could provide a molecular target for therapy [1] [2] [3] [4].

High impact information on S100A7A

• We used PCR to amplify an indel within intron 1 of the S100A7a (koebnerisin) and S100A7c (psoriasin) genes that gave the same two expected product sizes using 40 human DNA samples and 1 chimpanzee sample, therefore confirming the presence of the region 1 and 3 duplication in these species [5].
• Human S100A15 (koebnerisin) is a novel member of the S100 family of EF-hand calcium-binding proteins and was recently identified in psoriasis, where it is significantly upregulated in lesional skin [1].
• By sequence comparison, we have mapped the novel gene, named S100A15, to the S100 gene cluster within the epidermal differentiation complex (chromosome 1q21) [6].

Analytical, diagnostic and therapeutic context of S100A7A

• In situ hybridization of the S100A15 (koebnerisin) revealed a markedly increased staining of basal and suprabasal epidermal layers of psoriatic skin compared with healthy tissue [6].
• Sequence analysis of a 650-bp cDNA fragment (clone 110) that was highly up-regulated in lesional skin revealed homology to a noncoding cDNA (NICE-2) [6].
• Purification, crystallization and preliminary X-ray diffraction of human S100A15 (koebnerisin) [1].
• Northern blot hybridization and semiquantitative RT-PCR analysis confirmed the S100A15 (koebnerisin) overexpression in psoriasis, showing different levels of expression of the S100A15 mRNA isoforms [6].

References